Representative multikinase c-Met inhibitors include foretinib (XL880/GSK1363089), glesatinib (MGCD265), BMS-777607, and S49076, which target c-Met/RON/VEGFR-2/KIT/TIE2/PDGFR, c-Met/TIE2/RON/VEGFR-1/2/3, c-Met/RON/AXL, and c-Met/AXL/MER/FGFR, respectively.58–61 Several clinical trials were carried out to test their efficacy for cancer therapy, but some of the results have not been disclosed. Here, KDR is linked to cancer.